FDA Clearance for Accipio Ix™ Intracranial Hemorrhage Platform
Agreement will pave the way for integration of MaxQ AI’s artificial intelligence Accipio Ix™ intracranial hemorrhage software into NeuroLogica’s medical imaging platforms in the U.S. and E.U. acute care market
Tel Aviv, Israel and Andover, MA – November 7, 2018 – MaxQ AI, a clinical diagnostics intelligence platform company, today announced that its revolutionary Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance paves the way for healthcare providers and physicians in acute care settings to have access to this artificial intelligence (AI) software designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of intracranial hemorrhage (ICH), commonly known as a brain bleed.
Samsung NeuroLogica and MedyMatch Technology Announce Strategic Alliance to Bring “A.I. to the Curbside”
IBM AND MAXQ AI FORM A NEW GO-TO-MARKET
- IBM Watson Health Imaging signs multiyear OEM agreement to license MaxQ AI’s patient specific - point of care – cognitive decision support algorithms.
- The first application to be made available is MaxQ AI’s A.I. based intracranial hemorrhage detection.
- Go-To-Market will focus on the delivery of cognitive based clinical decision support tools to service the acute care marketplace through IBM Watson Health Imaging.
Tel Aviv, Israel – January 24, 2017 – IBM (NYSE: IBM) and MaxQ AI announced today a multi-year, go to market relationship to deliver MaxQ AI’s cognitive-based clinical decision support algorithms to the acute care marketplace. The initial application, to be distributed through IBM Watson Health Imaging’s platform is MaxQ AI’s intracranial hemorrhage detection algorithm.
Intracranial Bleed Detection Technology
Tel Aviv, Israel – November 22, 2016 – MedyMatch Technology Ltd., (“MedyMatch”) the deep learning and artificial intelligence company, announced today that after several years of extensive research and development, it has achieved a major milestone in the availability, for research, of an artificial intelligence-based technology that can help detect the presence of intracranial hemorrhage or brain bleed which can occur in cases of brain trauma and stroke. Subtle bleeds are difficult to detect and if misinterpreted or missed by a physician can lead to serious patient injury and even death.
Tel Aviv, Israel –July 21, 2016 – MedyMatch Technology Ltd., announced today that it has been ranked in the list of “100 Most Promising BigData Solution Providers” by CIOReview. A link to the article can be found here http://bigdata.cioreview.com/vendor/2016/medymatch.
MedyMatch Partners with Capital Health to Develop Artificial Intelligence Platform for Emergency Rooms
Hopewell Township, NJ and Tel Aviv, Israel – June 27, 2016 – MedyMatch Technology Ltd., the data analytics healthcare company focused on providing physicians with artificial intelligence, real-time decision support tools in the emergency room, announced today a partnership with Capital Health, the first of several partnerships with hospitals in the United States intended to improve stroke patient outcomes. As part of the agreement, Capital Health will provide anonymized data to MedyMatch for use in the development of its first decision support tool, directed towards stroke patients.
USES DEEP VISION AND COGNITIVE ANALYTICS TO INCREASE QUALITY OF CARE AND PATIENT OUTCOMES; FORMER PHILIPS IMAGING SYSTEMS CEO GENE SARAGNESE JOINS AS CHAIRMAN & CEO
Former Philips Imaging Systems CEO Gene Saragnese Joins as Chairman & CEO
Boston, MA, and Tel Aviv, Israel – February 17, 2016 – MedyMatch Technology, Ltd., the artificial intelligence healthcare startup, announced today its launch and vision to improve performance in healthcare with real-time decision support tools, starting in the Emergency Room. Additionally, the Company announced that Mr. Gene Saragnese joined as Chairman & Chief Executive Officer.